Cat. No.: DAB-0012681
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly717 of human PI3K class II α protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PIK3C2A |
| UniProt No. | O00443 |
| Gene ID | 5286 |
| Gene Description | Class II phosphatidylinositol 3-kinases contain a C-terminal C2 domain that is unique to the class II isoforms of the PI3K family. This C2 domain mediates protein and phospholipid binding acitivities. PI3K Class II α generates phosphatidylinositol 3-phosphate and phosphatidylinositol 3, 4-bisphosphate P2) from phosphatidylinositol and phosphatidylinositol 4-phosphate. PI3K Class II α is located in various intracellular locations such as the trans-Golgi network, endocytic compartments, clathrin-coated vesicles, and nuclear speckles. Research studies have indicated that PI3K Class II α regulates the assembly and distribution of clathrin, resulting in the modulation of clathrin-dependent trafficking and sorting within the trans Golgi network. PI3K Class II α also mediates translocation of the glucose transporter GLUT4 to the plasma membrane in response to insulin. PI3K Class II α has also been shown to regulate neurosecretory granule exocytosis and vascular smooth muscle contraction., like other PI3K family members, PI3K Class II α is less sensitive to the PI3K inhibitors wortmannin and LY294002. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
